Comparison of Interscalene Catheter to Single Injection Interscalene Blocks for Total Shoulder Arthroplasties
Melinda Seering · NCT05868330
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–90 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Phase 4
- Target enrollment
- 56
- US sites recruiting
- 1
- Study start
- August 19, 2024
- Record last updated
- November 10, 2025
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Comparison of post-operative pain after total shoulder surgery. The Principle Investigator will be comparing Exparel single shot block to Interscalene catheter
Being studied: Interscalene Catheter; Exparel Single Shot Interscalene Block
Conditions: Post Operative Pain; Anesthesia; Nerve Block; Shoulder Osteoarthritis
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
Patients who have or are
- Orthopedics service patients having reverse shoulder replacement surgery
- ASA class I, II, or III.
- Patients at least 18 years old but less than 90 years old.
- Patients giving informed consent.
- Non-Emergency Surgery
Exclusion Criteria
Patients who have or are
- An inability to cooperate during the block placement.
- Patients who do not meet criteria for a regional block: such as those on anti-coagulation,
- Significant pulmonary disease or allergy to medications used for peripheral nerve blocks (Exparel, Bupivacaine and Ropivacaine)
- Neuropathy of the planned extremity to block
- Documented Kidney Failure
- Documented Liver Failure
- A lack of or inability to give informed consent.
- Currently incarcerated.
- Pregnant
- Unable to communicate in English
- Chronic pre-operative opioid use (greater than 20 MME opioid used)
- Fracture
- Revision surgery
Recruiting US locations
University of Iowa Hospital and Clinics
Iowa City, IA 52242
Site contact: Melinda Seering, M.D. · 319-384-8075 · melinda-seering@uiowa.edu
Study contacts (from the official record)
- Melinda Seering, MD · 5156895508 · melinda-seering@uiowa.edu
Similar studies in Iowa
All arthritis studies in Iowa →- RecruitingPhase 1
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
AstraZeneca
- Location
- Iowa City, IA + 2 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 2
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
Artiva Biotherapeutics, Inc.
- Location
- Iowa City, IA + 29 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare
Atom Therapeutics Co., Ltd
- Location
- Des Moines, IA + 10 other US sites
- Eligibility basics
- Ages 18–70